top of page
Executive Spotlights

Summit bets $5B on Akeso, $500million upfront, and milestone payments of $4B for cancer therapy deal

Cambridge, MA, December 6, 2022 (Reuters) -- Summit Therapeutics Inc (SMMT.O) said on Tuesday it would license China-based Akeso Inc's (9926.HK) experimental cancer therapy in a deal worth up to $5 billion, sending its shares up 57% in premarket trade.


Read full article here.


Recent Posts

See All

Santa Clara, CA, January 17, 2023 (RTTNews) -- Shockwave Medical, Inc. (SWAV) has entered into a definitive agreement to acquire Neovasc Inc. (NVCN). Shockwave will acquire all outstanding Neovasc s

Life Science Headlines
bottom of page